Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799442 | 0.96 | HRH3 (0.50) | LMNAHRH3KMT2AMEN1CARM1 | |
| SCHEMBL3553239 | 0.96 | LMNA (0.44) | LMNAHRH3KMT2AMEN1CARM1 | |
| SCHEMBL348065 | 0.96 | HRH3 (0.50) | LMNAHRH3KMT2AMEN1CARM1 | |
| SCHEMBL7007038 | 0.96 | HRH3 (0.50) | LMNAHRH3KMT2AMEN1CARM1 | |
| Hydrochloric Acid SCHEMBL10442200 | 0.92 | HRH3 (0.47) | LMNAHRH3KMT2AMEN1CARM1 | |
| Hydrochloric Acid SCHEMBL22322297 | 0.92 | HRH3 (0.47) | LMNAHRH3KMT2AMEN1CARM1 | |
| SCHEMBL3558131 | 0.92 | HRH3 (0.47) | LMNAHRH3KMT2AMEN1CARM1 | |
| SCHEMBL13776923 | 0.91 | — | — | |
| SCHEMBL20363777 | 0.89 | LMNA (0.40) | LMNAHRH3KMT2AMEN1CARM1 | |
| Hydrochloric Acid SCHEMBL10442465 | 0.89 | HRH3 (0.45) | LMNAHRH3KMT2AMEN1CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200283387-A1 | METHOD FOR PREPARING METHIONINE ANALOGUES | ADISSEO FRANCE S.A.S. (FR) | 2020-09-10 | — | — | US | claimed |
| EP-3405452-A1 | METHOD FOR PREPARING METHIONINE ANALOGUES | Adisseo France S.A.S. (FR) | 2018-11-28 | — | — | EP | claimed |
| EP-2957575-B1 | OPTICALLY ACTIVE POLY(DIPHENYLACETYLENE) COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF AS OPTICAL ISOMER SEPARATING AGENT | NAT UNIV CORP KANAZAWA UNIV (JP) | 2017-10-18 | — | — | EP | claimed |
| WO-2017125673-A1 | METHOD FOR PREPARING METHIONINE ANALOGUES | ADISSEO FRANCE S.A.S. (FR) | 2017-07-27 | — | — | WO | claimed |
| US-9562121-B2 | Optically active poly(diphenylacetylene) compound, preparation method therefor, and use thereof as optical isomer separating agent | NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY (JP) | 2017-02-07 | — | — | US | claimed |
| US-20160194291-A1 | STYRYL QUINAZOLINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE AGENTS | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2016-07-07 | — | — | US | claimed |
| EP-3030550-A1 | STYRYL QUINAZOLINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE AGENTS | Vichem Chemie Kutató KFT (HU) | 2016-06-15 | — | — | EP | claimed |
| US-9290592-B2 | Poly(diphenylacetylene) compound, preparation method therefor, and use thereof as optical isomer separating agent | NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY (JP) | 2016-03-22 | — | — | US | claimed |
| US-20150376308-A1 | OPTICALLY ACTIVE POLY(DIPHENYLACETYLENE) COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF AS OPTICAL ISOMER SEPARATING AGENT | NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY (JP) | 2015-12-31 | — | — | US | claimed |
| US-20150376309-A1 | NEW POLY(DIPHENYLACETYLENE) COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF AS OPTICAL ISOMER SEPARATING AGENT | National University Corporation Kanazawa University of Ishikawa ,Japan | 2015-12-31 | — | — | US | claimed |
| WO-2015019121-A1 | STYRYL QUINAZOLINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE AGENTS | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2015-02-12 | — | — | WO | claimed |
| EP-2091951-A2 | PYRIDO[2,3-B]PYRAZINE AND[1,8]-NAPHTYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2009-08-26 | — | — | EP | claimed |
| WO-2007130468-A2 | PYRIDO [2, 3-B] PYRAZINE AND [1, 8] -NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2007-11-15 | — | — | WO | claimed |
| CN-1213684-A | Chemical Mechanical Polishing Composition | CHANGXING CHEMICAL IND CO LTD (CN) | 1999-04-14 | — | — | CN | claimed |
| US-5750688-A | REACTING AN HALOGENATED AMINE WITH AN OXYBENZOIC ESTER; THEN A 2-(OXYPHENYL-)BENZOTHIOPHENE COMPOUND | ELI LILLY AND COMPANY (US) | 1998-05-12 | — | — | US | claimed |
| EP-0729956-A1 | Benzothiophene compounds, intermediates, compositions, and methods | ELI LILLY AND COMPANY (US) | 1996-09-04 | — | — | EP | claimed |
| US-5324837-A | 3,4-disubstituted-4,5-dihydro-1H-pyrazoles and a method of preparation | DOWELANCO (US) | 1994-06-28 | — | — | US | claimed |
| EP-0548226-A1 | MONOSACCHARIDES HAVING ANTI-PROLIFERATION AND ANTI-INFLAMMATORY ACTIVITY, COMPOSITIONS AND USES THEREOF | GREENWICH PHARMACEUTICALS INCORPORATED (US) | 1993-06-30 | — | — | EP | claimed |
| WO-1992004359-A2 | MONOSACCHARIDES HAVING ANTI-PROLIFERATION AND ANTI-INFLAMMATORY ACTIVITY, COMPOSITIONS AND USES THEREOF | GREENWICH PHARMACEUTICALS, INC. (US) | 1992-03-19 | — | — | WO | claimed |
| US-3985768-A | Process for producing rolitetracycline | E. R. SQUIBB & SONS, INC. (US) | 1976-10-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283387-A1 | METHOD FOR PREPARING METHIONINE ANALOGUES | GRM4, CHRM4, GRIA4 | LMNA 3516/4885HRH3 415/4885KMT2A 1763/4885 |
| US-20160194291-A1 | STYRYL QUINAZOLINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE AGENTS | FLT3, BCR, STK3 | LMNA 3239/4885HRH3 765/4885KMT2A 3110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.